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Evidence for Abnormal Regulation of Circulating
la,25-Dihydroxyvitamin D in Patients
with Sarcoidosis and Normal Calcium Metabolism
PAULA H. STERN, JOSE DE OLAZABAL, and NORMAN H. BELL, Department of
Pharmacology, Northwestern University Medical School,
Chicago, Illinois 60611; Veterans Administration Hospital and
Departments of Medicine and Pharmacology, Medical University of
South Carolina, Charleston, South Carolina 29403

A B S T R A C T The effects of vitamin D, 2.5 mg
(100,000 U)/d for 4 d, on serum calcium, serum 25hydroxyvitamin D (25-OHD), and serum 1a,25-dihydroxyvitamin D [la,25(OH)2D] were compared in 17
normal subjects and 6 patients with sarcoidosis who
had normocalcemia and no history of hypercalcemia.
The diagnosis was confirmed histologically in each of
them. Vitamin D increased mean serum 25-OHD from
30±4 to 99±15 nglml (P < 0.001) and did not change
mean serum 1a,25(OH)2D (32±3 vs. 29±3 pg/ml) or
mean serum calcium (9.5±0.1 vs. 9.6±0.1 mg/dl) in the
normal subjects. In contrast, vitamin D increased mean
serum 25-OHD from 19±3 to 65±19 ng/ml (p < 0.05),
increased mean serum la,25(OH)2D threefold from
40±7 to 120±24 pg/ml, and increased mean serum
calcium from 9.4±0.2 to 9.8±0.2 mg/dl (P < 0.01).
There was a significant positive correlation between
the serum la,25(OH)2D and serum calcium in these
individuals (r = 0.663, P < 0.01) but not in the normal
subjects. The results (a) provide further evidence for
abnormal regulation of circulating la,25(OH)2D in
sarcoidosis and (b) indicate that the abnormality
may exist in patients with normal calcium metabolism.
Thus, the defect in vitamin D metabolism in sarcoid
apparently is more common than was previously
recognized.

METHODS

INTRODUCTION

Available evidence indicates that the abnormal calcium metabolism in sarcoidosis results from increases
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in circulating la,25-dihydroxyvitamin D [la,25(OH)2D].' Mean plasma la,25(OH)2D is increased and
serum immunoreactive parathyroid hormone is suppressed in patients with sarcoidosis and hypercalcemia who do not have primary hyperparathyroidism (1, 2). Further vitamin D, 0.25 mg (10,000 U)/d
for 12 d, increases serum la,25(OH)2D abnormally in
patients with normocalcemia and a history of hypercalcemia but does not alter serum la,25(OH)2D abnormally in subjects or patients with sarcoid who have
normal calcium metabolism (1). Thus, the increased
sensitivity to vitamin D in sarcoid results from increases in serum la,25(OH)2D. Finally, hypercaleemia
and the increases in circulating la,25(OH)2D are corrected after treatment with glucocorticoids (1, 2).
In our previous investigation this dose of vitamin D
produced a modest but significant increase in mean
serum la,25(OH)2D (which remained well within the
normal range) in the patients with sarcoidosis and
normal calcium metabolism (1). To determine whether
an abnormal response of serum la,25(OH)2D might
be elicited with a larger dose of vitamin D, the
effects of 2.5 mg (100,000 U)/d for 4 d of the vitamin
were compared in normal subjects and patients
with sarcoidosis who had a normal serum calcium
and had never had hypercalcemia.
17 adult normal subjects, 9 men and 8 women ranging in
age from 21 to 56 yr, and 6 patients with sarcoidosis, 4 men
and 2 women ranging in age from 23 to 58 yr, were studied.
They were hospitalized at the Clinical Research Center of
the Indiana University Medical School or of the Medical
University of South Carolina. Each of them was given a con-

'Abbreviations used in this paper: la,25(0H)2D, la,25dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin D.
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relation coefficient was carried out with a Hewlett-Packard
calculator (model 9815A, Hewlett-Packard Co., Palo Alto,
Calif.).

TABLE I

Clinical Findings in Patients with Sarcoidosis
HyperPatient

Age

Sex

58
27
33
26
31
23

calcemia*

112

+
+

174
255
86
156

+

-

Urinary Ca

rngldl

mngld

9.0
9.4
9.2
9.5
9.6
9.6

yr

A
B
C
D
E
F

Biopsy

Serum Ca

F
M
F
M
M
M

+
+
+

RESULTS

* By history.

stant daily diet estimated to contain 400 mg/d of calcium
and 900 mg of phosphorus and a constant fluid intake. V'itamin
D2, 2.5 mg (100,000 U)/d for 4 d, was givein as a single
morning dose. Fasting blood samples were obtained on the
1st d before vitamin D and again on the 5th d, 24 h after the
last dose of the vitamin, for determination of calcium (3, 4),
phosphorus (5), creatinine (6, 7), 25-hydroxyvitamin D (25OHD), and la,25(OH)2D. In the patients, 24-h urines were
collected and analyzed for calcium (4).
Serum 25-OHD was measured in triplicate by the competitive protein-binding method with vitamin D-deficient
rat serum (8) as described (1). The normal range for the
method in this laboratory is from 10 to 80 ng/ml (1).
Serurn la,25(OH)2D was measured by bioassay as described
(1, 9). The mean value in normal subjects is 32+2 pg/ml and
the range is from 15 to 55 pg/ml (n = 33). The 95% confidence values (mean±2 SD) are 13-52 pg/ml. The interassay
variation is 9.1 % (n = 17).
Student's t test was used to determine the significance of
differences between paired or unpaired samples (10). Cor-

The diagnosis of sarcoidosis was confirmed histologically in each of the patients (Table I). None of
them had had hypercalcemia and none had received
steroids for at least 1 yr before the study. Serum calcium was normal in each of them and urinary calcium was above 200 mg/d in one of them.
The effects of vitamin D, 2.5 mg/d for 4 d, were
examined in 17 normal subjects and in 6 patients
with sarcoid (Table II). In the normal subjects
vitamin D increased mean serum 25-OHD significantly,
but did not alter mean serum calcium, phosphorus,
creatinine, or la,25(OH)2D.
In contrast, vitamin D increased mean serum calcium, phosphorus, 25-OHD, and la,25(OH)2D and
did not change mean serum creatinine in the patients.
The increases in serum la,25(OH)2D ranged from
57% in patient F to 797% in patient D and averaged
195%. Whereas before vitamin D mean serum
la,25(OH)2D was not significantly different between
the normal subjects and patients, after vitamin D it was
significantly higher in the patients than in the normal
subjects (P < 0.001). Furthermore, there was a significant positive correlation between the serum
la,25(OH)2D and serum calcium in the patients
(Fig. 1) but not in the normal subjects. Urinary calciuim averaged 116, 139, 239, 72, and 214 mg/d

TABLE II
Effects of Vitamin D2 on Serum Calcium, Phosphorus,
Creatiniine, 25-OHD, and 1 a, 25(OH)2D
Seruimii

Normal subjects (17)
Control
Vitamin Dt
P value
Patients (6)
Control
Vitamin Dt
P value

Calctiulm

Phosphortus

cre.atininie

25-OHD*

la,25(OH),D

nzgldl

rmigldl

rmlg/dl

rlglgil

pgnid

9.5±0.1
9.6+0.1

4.1±0.1
4.1+0.1

0.9±0.1
1.0±0.1

30+4

99±15

NS

NS

NS

<0.001

32+3
29+3
NS

9.4±0.2

3.9±(0.3

1.0±0.1

19±3

40+7

9.8+0.2
<0.01

4.2+0.3
<0.01

1.0+0.1
NS

65+19
<0.05

120±24§
NS

Results are given as mean±SE.
Serum 25-OHD was measured in 12 normals before vitamin D and in 9 normals
after vitamin D.
Vitamin D2, 2.5 imig/d for 4 d, was given by mooth.
§ The difference letween control ancd treated valtues is not significant (t =2.05)
I)ecause of the marked increase in sertum la,25(OH)2D from 34 to 305 pg/ml in
patient D. If these vallues are omitted, mean serum la,25(OH)2D increased from
42±8 to 83±+13 pg/ml (t = 6.06, P < 0.01) in the other patients.
*
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10.6r

contrast, vitamin D intoxication in the cow is characterized by increases in all of the metabolites of
vitamin D including the vitamin itself, 25-OHD, 24,25'0
dihydroxyvitamin D, as well as la,25(OH)2D (14).
10.2 0
Urinary calcium did not change appreciably during
E
the 4 d of treatment with vitamin D in our patients
E
despite the increases in serum la,25(OH)2D and
.5 9.81modest but significant increases in serum calcium,
remained within the normal range. We demwhich
E
previously in two patients with sarcoid and
onstrated
9.4 (I)
a history of hypercalcemia that vitamin D, 250 ug/d
for 12 d, increased both serum la,25(OH)2D and
calcium. Serum calcium remained within the
urinary
9.0
normal range. The increases in serum la,25(OH)2D
.
L.
were noted by the 5th d of administration of vitamin D
160 320 640
80
40
20
10
and preceded the increases in urinary calcium. Urinary
Serum 1,25 (OH)2D pg/mi
calcium did not change during the initial 4 d of vitamin
FIGURE 1 Effects of vitamin D2 on serum la,25(OH)2D and D. Thus, the period of observation in the present
serum calcium in six patients with sarcoidosis. Note that study was too short an interval for an increase in
the serum la,25(OH)2D is drawn on a semi-log plot. urinary calcium to occur.
r = 0.663; P < 0.01.
o Control
* Vitamin D
2.5 mg /day x 4 days

t-
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of circulating 1a,25(OH)2D in a group of patients
with sarcoid and apparent normal calcium metabolism.
The results provide additional evidence that increases in serum la,25(OH)2D are responsible for the 1.
abnormal calcium metabolism in this disease (1, 2) and
suggest that the defect in vitamin D metabolism
is more common than was previously recognized.
The mechanism for the abnormal vitamin D metabo- 2.
lism in sarcoidosis has not been elucidated. Hypercalcemia was recently reported in a patient with
sarcoid who had developed renal failure and had
undergone bilateral nephrectomy in preparation for 3.
kidney transplantation (11). The hypercalcemia re$ponded to steroids and was associated with sup- 4.
pression of serum immunoreactive parathyroid hormone and increases in serum la,25(OH)2D. Serum 5.
calcium and serum la,25(OH)2D values correlated with
each other. The findings in this patient support the 6.
possibility that in sarcoid the production of 1a,25(OH)2D
7.
may occur in tissues other than that of the kidney.
Our observations in normal subjects suggest that the 8.
renal production of la,25(OH)2D is tightly regulated.
The findings are consistent with those obtained in
patients with vitamin D intoxication, who show increases in serum 25-OHD and not la,25(OH)2D 9.
(12). In the rat, vitamin D intoxication with hypercalcemia is characterized by increases in serum 25OHD and decreases in serum la,25(OH)2D (13). In 10.
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